ArticlePulmonary therapy2023

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis.

Michael S Schechter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.